Navigation Links
MIGENIX releases CEO message #22
Date:2/15/2008

ease contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, and forward-looking information within the meaning of applicable securities laws in Canada, (collectively referred to as "forward-looking statements"). Statements, other than statements of historical fact, are forward-looking statements and include, without limitation, statements regarding our strategy, future operations, timing and completion of clinical trials, prospects, plans and objectives of management. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other things contemplated by the forward-looking statements will not occur.

Although our management believes that the expectations represented by such forward-looking statements are reasonable, there is significant risk that the forward-looking statements may not be achieved, and the underlying assumptions thereto will not prove to be accurate. Forward-looking statements in this news release include, but are not limited to, statements concerning our expectations for: Phase III OmigardTM trial results in the second half of 2008 and if the results of this trial are positive, a new drug application (NDA) being submitted for OmigardTM in the first half of 2009; celgosivir Phase II viral kinetic results in the third quarter 2008; CLS001 entering into Phase III clinical development, partnerships; and other progress expected in 2008 and into 2009.

With respect to the forward-looking statements contained in this news release, we have made numerous assumptions regarding, among other things: Cadence's ability to enroll sufficient patients to complete the OmigardTM Phase III trial; the adequacy of the OmigardTM trial design to generate data that are deemed sufficient by regulatory authorities to support po
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
2. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
3. MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
4. MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
5. MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
6. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
7. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
8. National Nanotechnology Initiative releases its fiscal year 2009 budget and highlights
9. CellCyte Genetics Corp. Continues to Move Its Technology Forward in Light of Plaintiff Law Firm Press Releases
10. Intrasphere Technologies Releases PharmaCM Submissions Management and Authoring Module Powered by Microsoft Office SharePoint Server 2007
11. Techne Corporation Releases Unaudited Second Quarter Results for Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... -- , Not for release, publication or distribution ... jurisdiction where to do so would constitute a violation of ... ("Shire" or the "Company") (LSE: SHP, NASDAQ: SHPG ... has held a meeting with representatives of AbbVie. ... agreement or approval of AbbVie. A further update ...
(Date:7/11/2014)... July 11, 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. ... (eslicarbazepine acetate) for use as a once-daily adjunctive ... with epilepsy who are not satisfactorily controlled with conventional ... in patients under 18 years of age. ... disorders and according to Epilepsy Canada, it affects 0.6% ...
(Date:7/10/2014)... July 10, 2014 Product and ... very low abundance and are often “lost in ... time-consuming. , Join presenters Dr. Rowel Tobias, Senior ... John Anders, Head of Quality at Nanotherapeutics, Inc., ... that can speed detection and quantitation while achieving ...
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 Unraveling ... closer together. The Archer Family purchased a ... within DNA, but ended up with a lifetime of ... contained within the family members’ DNA genuinely brought the ... decided to search deeper into genetic history and prior ...
Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5
... Cover the Use of Pharsight Software for In-Vitro / ... Correlation Modeling ... Pharsight(R),Corporation (Nasdaq: PHST ), a leading provider ... drug,development, today announced that Jason Chittenden, MS, Director of,Training ...
... (Nasdaq:,INSM), a developer of follow-on biologics and biopharmaceuticals, ... before The NASDAQ Listing,Qualifications Panel (,the Panel") to ... common stock from The NASDAQ Capital Market., ... Market ("NASDAQ") on,June 17, 2008 indicating that the ...
... / b3c newswire /  - Rentschler Biotechnologie, ... Arzneimittel gibt die Inbetriebnahme einer 2.500 Liter ... über neun unabhängige GMP-Produktionslinien mit Arbeitsvolumen von ... die Herstellung von klinischen Prüfmustern und für ...
Cached Biology Technology:Pharsight to Present on IVIVC at Bioequivalence & Bioavailability Strategies Conference 2Pharsight to Present on IVIVC at Bioequivalence & Bioavailability Strategies Conference 3Insmed to Request Hearing Before NASDAQ Panel to Review NASDAQ Staff Determination 2Rentschler Biotechnologie erweitert Kapazitten fr Produktion in Sugetierzellen 2
(Date:7/10/2014)... , July 1, 2014 Smart ... way for convenience and improved security: NXT-ID, Inc. (OTCBB: NXTD), ... GOOG ), Apple Inc. (NASDAQ: AAPL ... Corporation (NYSE: MA) NXT-ID, Inc., (OTCQB: NXTD) a biometric ... to announce that the second series of 30 second spots ...
(Date:7/10/2014)... NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication company focused on the growing ... was interviewed on July 1 st on the Downtown ... Mr. Pereira discusses the company,s next generation smart wallet with ... Wocket™ aims to replace a traditional wallet with a new ... tells Gino he has never heard of the Wocket and ...
(Date:7/10/2014)... , July 7, 2014 Fingerprint Cards, ... major design win (DW). A Chinese Top 5 smartphone OEM ... start of mass production in October 2014.   ... Top 5 smartphone OEM, which has a planned date for ... target sales volume for this phone of 3 million units. ...
Breaking Biology News(10 mins):Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 2Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 3Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 4Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 5Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 2Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 4FPC Wins DW for 1021 Touch Sensor for Flagship Smartphone from Chinese Top 5 Smartphone OEM 2
... -- (Oct. 20, 2011) -- Junrong Zheng,s techniques to see ... young Rice University scientist a highly prestigious Packard Fellowship. ... students will use the five-year grant that comes with the ... the conformation -- the shape and orientation -- of any ...
... Rochelle, NY, October 20, 2011Spas that offer massage therapy ... levels of potentially harmful indoor air pollutants such as ... an article in Environmental Engineering Science , a ... . The article is available free online at ...
... the association for informatics professionals, honors four leaders ... to be presented during AMIA,s Annual Symposium, Oct. ... professionals to the Washington Hilton over the coming ... whose contributions to the health sector have had ...
Cached Biology News:Rice's Zheng wins Packard Fellowship 2Can aromatherapy produce harmful indoor air pollutants? 2AMIA honors informatics professionals who are improving health, changing the world 2AMIA honors informatics professionals who are improving health, changing the world 3
...
Rabbit polyclonal to MCP2 ( Abpromise for all tested applications). entrezGeneID: 6355 SwissProtID: P49873...
Mouse monoclonal antibody raised against a partial recombinant AATK. NCBI Entrez Gene ID = AATK...
... AS-2057 are fully automatic sample injection systems ... of precision. Sampling flexibility is unparalleled with ... automation and combinatorial chemistry. Also available is ... standard rack for 50 2,ml vials. The ...
Biology Products: